Aarhus University Seal

Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review


Plasmacytoid dendritic cells (pDCs) are multifaceted immune cells with a wide range of innate and adaptive immunological functions. They constitute the first line of defence against multiple viral infections and have also been reported to actively participate in antitumor immune responses. The clinical implication of the presence of pDCs in the tumor microenvironment (TME) is still ambiguous, but it is clear that pDCs possess the ability to modulate tumor-specific T cell responses and direct cytotoxic functions. Therapeutic strategies designed to exploit these qualities of pDCs to boost tumor-specific immune responses could represent an attractive alternative compared to conventional therapeutic approaches in the future, and promising antitumor effects have already been reported in phase I/II clinical trials. Here, we review the many roles of pDCs in cancer and present current advances in developing pDC-based immunotherapeutic approaches for treating cancer.

Original languageEnglish
Article number11397
JournalInternational Journal of Molecular Sciences
Publication statusPublished - Sep 2022

Bibliographical note

Publisher Copyright:
© 2022 by the authors.

    Research areas

  • melanoma, pDC-based vaccines, plasmacytoid dendritic cells, tumor-specific immune responses, Dendritic Cells, T-Lymphocytes, Humans, Immunotherapy, Neoplasms/drug therapy, Tumor Microenvironment

See relations at Aarhus University Citationformats

ID: 285909604